Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR Tucci, RP Tonino, RD Emkey, CA Peverly… - The American journal of …, 1996 - Elsevier
OBJECTIVE: Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated
bone resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind …
bone resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind …
[引用][C] Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR TUCCI, RP TONINO, RD EMKEY… - … American journal of …, 1996 - pascal-francis.inist.fr
Effect of three years of oral alendronate treatment in postmenopausal women with
osteoporosis CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
osteoporosis CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
Effect of Three Years of Oral Alendronate Treatment in Postmenopausal Women with Osteoporosis
JR Tucci, RP Tonino, RD Emkey, CA Peverly… - The American Journal of …, 1996 - infona.pl
objective: Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated bone
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
JR Tucci, RP Tonino, RD Emkey… - The American Journal …, 1996 - europepmc.org
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
- Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
- Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR Tucci, RP Tonino, RD Emkey… - … journal of medicine, 1996 - pubmed.ncbi.nlm.nih.gov
Objective Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated bone
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
[引用][C] Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR Tucci, RP Tonino, RD Emkey, CA Peverly… - The American Journal …, 1996 - cir.nii.ac.jp
Effect of three years of oral alendronate treatment in postmenopausal women with
osteoporosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
osteoporosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR Tucci, RP Tonino, RD Emkey, CA Peverly… - The American Journal …, 1996 - amjmed.com
Objective Oral alendronate sodium is a potent, specific inhibitor of osteoclast-mediated bone
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
resorption. To assess its efficacy and safety, a 3-year, randomized, double-blind, multicenter …
[引用][C] Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
JR TUCCI - Am. J. Med., 1996 - cir.nii.ac.jp
Effect of three years of oral alendronate treatment in postmenopausal women with
osteoporosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
osteoporosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …